Therapeutic Strategies With Selective CDK4/6 Inhibitors: An Oncologist’s Guide to Safe Inhibition of Uncontrolled Cellular Proliferation in Solid Tumors

Review recent developments with selective CDK4/6 inhibitors in the care of patients with various cancers in this certified text module, on-demand Webcast, and accompanying slideset developed by Richard Finn, MD; Geoffrey Shapiro, MD, PhD; and Gary K. Schwartz, MD.
Richard Finn, MD
Program Director
Richard Finn, MD
Gary K. Schwartz, MD
Geoffrey Shapiro, MD, PhD

Selective CDK4/6 Inhibitors in Cancer: Moving Beyond Breast Cancer

Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, discuss the supporting rationale and emerging role of selective CDK4/6 inhibitors in multiple types of cancer.

Richard Finn, MD Gary K. Schwartz, MD Geoffrey Shapiro, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 14, 2017 Expiration: April 13, 2018

The first of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review critical data on the mechanisms of CDK4/6 inhibition and its clinical effects in various cancer types.

Released: June 8, 2017

The second of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review critical studies on the clinical and preclinical characteristics of CDK4/6 inhibitors in multiple tumor types.

Released: June 8, 2017

The third of 3 downloadable slidesets from a satellite symposium at the 2017 annual meeting in Chicago: Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, review key data on combining CDK4/6 inhibitors with hormone therapy, PI3K inhibitors, and others in multiple cancers.

Released: June 8, 2017

In this downloadable slideset, Richard Finn, MD, Gary K. Schwartz, MD, and Geoffrey Shapiro, MD, PhD provide insight on the rationale for targeting cyclin dependent kinases 4 and 6 in cancer and highlight emerging clinical data with selective CDK4/6 inhibitors in multiple cancers.

Released: April 14, 2017

On-Demand Webcast

In this Webcast from a satellite symposium at the 2017 annual meeting in Chicago, expert insights on the biology and emerging role of CDK4/6 inhibitors in multiple tumor types are provided by Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD.

Richard Finn, MD
Program Director
Gary K. Schwartz, MD Geoffrey Shapiro, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 13, 2017 Expiration: July 12, 2018
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by an educational grant from
Pfizer Inc.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?